Introduction
Phencyclidine (PCP) is a psychotomimetic drug that induces various behavioral, emotional, and cognitive changes in animals by blocking neurotransmission at N-methyl-D-aspartate-type glutamate receptors. Many animal models of schizophrenia have been developed on the basis of this property of PCP (Javitt and Zukin, 1991; Chen et al., 2011; Javitt et al., 2012) . Among these, PCPinduced hyperlocomotion is a widely used behavioral screening tool to identify potential antipsychotic-like compounds and study the behavioral and neurobiological mechanisms of antipsychotic action, as many commonly used antipsychotic drugs, such as haloperidol, clozapine, and olanzapine, but not anxiolytics or antidepressants, suppress PCP-induced hyperlocomotion upon acute drug administration (Redmond et al., 1999; Porsolt et al., 2010; . With repeated drug administration, antipsychotics (e.g. haloperidol, clozapine, or olanzapine) progressively potentiate inhibition of repeated PCP-induced hyperlocomotion and prolong this action over several test sessions (Sun et al., 2009) , whereas repeated administration of anxiolytics (e.g. chlordiazepoxide) or antidepressants (e.g. fluoxetine and citalopram) either does not affect PCP-induced hyperlocomotion or may even enhance it (Redmond et al., 1999) . Thus, the repeated PCP-induced hyperlocomotion test is effective in distinguishing antipsychotic drugs from other psychotherapeutic drugs and in capturing the time course of an antipsychotic's clinical effects (Agid et al., 2006) .
Another interesting finding from the repeated PCPinduced hyperlocomotion studies is that when rats are later administered a challenge dose of the drug, those that have been treated repeatedly with haloperidol or olanzapine show a sensitization effect as they often have lower PCP-induced hyperlocomotion than vehicle-pretreated rats (Zhang and Li, 2012) . In contrast, rats treated previously with clozapine show higher PCP-induced hyperlocomotion than those that are treated with clozapine for the first time, indicating a tolerance-like effect (Feng et al., 2013) . These findings indicate that when an antipsychotic drug is administered repeatedly and intermittently, there is often a long-term alteration (increase or decrease) in its behavioral efficacy, a phenomenon commonly associated with drugs of abuse (Pierce and Kalivas, 1997; Siegel et al., 2000) .
Recent evidence shows that the context surrounding drug administration can powerfully modulate behavioral efficacy in the PCP-induced hyperlocomotion model (Zhang and Li, 2012; Feng et al., 2013) . In those studies, we used a novel across-model transfer paradigm in which we first treated rats repeatedly with haloperidol, olanzapine, or clozapine and tested them in a conditioned avoidance response model (another behavioral test with high predictive validity for drugs that have antipsychotic efficacy in humans) for 5 consecutive days. They were then tested for the expression of haloperidol and olanzapine sensitization, and clozapine tolerance in the PCPinduced hyperlocomotion model. We found that previous treatment with haloperidol, olanzapine, or clozapine in the avoidance response model did not alter their acute efficacy in the inhibition of PCP-induced hyperlocomotion. When tested in the PCP model, rats treated previously with these drugs did not show an immediate stronger (in the case of haloperidol and olanzapine) or weaker (in the case of clozapine) inhibition of PCP-induced hyperlocomotion than those treated with these drugs for the first time. However, when tested in the avoidance response model where the original antipsychotic treatment took place, rats treated previously with these drugs did show a stronger or a weaker inhibition of avoidance response. These results suggest that the behavioral effects of antipsychotic drugs are strongly modulated by the drug test environment and selected behavioral response, showing a contextdependent feature.
It is conceivable that various experimental parameters, such as schedule of injections, drug dose, and similarities between different environmental cues, all play a role in the regulation of the environmental control of antipsychotic efficacy. Because the situational impact on antipsychotic efficacy is a little studied phenomenon, compared with the long history of research on the contextual control of the behavioral effects of drugs of abuse (Siegel, 1975 (Siegel, , 1977 Siegel et al., 2000) , it is necessary to delineate the exact conditions that facilitate or reduce the ability of antipsychotics to inhibit PCP-induced hyperlocomotion and compare this research with the large body of literature concerned with drugs of abuse (Siegel, 1978; Poulos et al., 1981; Vezina and Stewart, 1984; Anagnostaras and Robinson, 1996; Robinson et al., 1998; Siegel et al., 2000) . One critical question that is yet to be addressed is whether it is possible to induce any change in the behavioral efficacy of an antipsychotic drug even when previous treatment occurs in a different environment. In other words, is it possible to observe a context-independent change in antipsychotic efficacy because of repeated drug administration? If the answer to this question is yes, this would have important clinical implications. For example, if the manipulation of environmental cues cannot completely prevent the occurrence of drug-induced change in behavioral efficacy, this would suggest that the repeated treatment effects may be mainly mediated by the neuroadaptive processes initiated by the interaction of a drug and its receptors (e.g. dopamine D 2 or serotonin 5-HT 2A receptors). Therefore, the treatment settings (e.g. home or hospital) may not be critical for the expression and maintenance of the therapeutic effects in patients.
In this study, we investigated possible conditions within which contextual control of the behavioral efficacy of haloperidol, olanzapine, and clozapine operates in the PCP-induced hyperlocomotion model. Two approaches were explored. In experiment 1, we assessed the extent to which previous antipsychotic treatment in one environment (home cage) affected a drug's inhibition of PCPinduced hyperlocomotion in another environment (test environment). In experiment 2, we varied the number of pairings of antipsychotic treatment in either the home environment or the test environment (e.g. 4, 2, or 0) and tested how a drug's inhibition of the PCP-induced hyperlocomotion was altered by different pairings.
Methods

Subjects
All experimental treatments and procedures were approved by the Institutional Animal Care and Use Committee at the University of Nebraska-Lincoln. Adult male Sprague-Dawley rats (226-250 g upon arrival; Charles River, Portage, Michigan, USA) were housed two per cage in 48.3 × 26.7 × 20.3 cm transparent polycarbonate cages under 12-h light/dark conditions (light on between 6:30 a.m. and 6:30 p.m.). Room temperature was maintained at 22 1°C with a relative humidity of 45-60%. Food and water were freely available. Animals were allowed at least 5 days of habituation to the animal facility before being used in experiments. All behavioral tests were performed during the light phase.
Locomotor activity monitoring apparatus
This apparatus has been described previously (Sun et al., 2009; Feng et al., 2013) . Sixteen activity boxes were housed in a quiet room. The boxes were 48.3 × 26.7 × 20.3 cm transparent polycarbonate cages, which were similar to the home cages, but were each equipped with a row of six photocell beams (7.8 cm between two adjacent photobeams) placed 3.2 cm above the floor of the cage. A computer with recording software (Aero Apparatus Sixbeam Locomotor System v1.4; Aero Apparatus Inc., Toronto, Ontario, Canada) was used to detect the disruption of the photocell beams and recorded the number of beam breaks. All experiments were run during the light cycle.
Experiment 1: effects of previous antipsychotic treatment in the home cages on the inhibitory effect of an antipsychotic drug on phencyclidine-induced hyperlocomotion This experiment examined the impact of the context on antipsychotic efficacy by testing how previous exposure to an antipsychotic drug in the home-cage environment (home environment) affects the drug's efficacy in the inhibition of PCP-induced hyperlocomotion in a motor activity test environment (test environment). We compared rats that were treated repeatedly with haloperidol, clozapine, or olanzapine in the home cages for 5 consecutive days with those that were treated with vehicle.
Forty-eight rats were assigned randomly to one of seven groups. From day 1 to 5 (5 consecutive days), four groups of rats were injected with sterile water in their home cages. They were denoted as the VEH + VEH (n = 6), VEH + HAL (n = 7), VEH + CLZ (n = 7), and VEH + OLZ (n = 7) groups. Three groups received haloperidol (0.05 mg/kg, n = 7), clozapine (10.0 mg/kg, n = 7), or olanzapine (2.0 mg/kg, n = 7) treatment in their home cages during this period. They were denoted as the HAL + HAL, CLZ + CLZ, and OLZ + OLZ groups. From day 6 to 10 (5 consecutive days), all rats were tested for their PCP-induced hyperlocomotion in the test apparatus. On each of the PCP test days, rats were first injected with either sterile water (for the VEH + VEH group), haloperidol [0.05 mg/kg, subcutaneously (sc), for the VEH + HAL and HAL + HAL groups], clozapine (10 mg/kg, sc, for the VEH + CLZ and CLZ + CLZ groups), or olanzapine (2.0 mg/kg, sc, for the VEH + OLZ and OLZ + OLZ groups), and then immediately placed in the boxes for 30 min. Any drug effect during this period reflects the effect on spontaneous motor activity. At the end of the 30-min period, they were taken out and injected with PCP (3.20 mg/kg, sc) and placed back in the boxes for another 60 min. The drug effect during this period reflects the antipsychotic-like effect on PCPinduced increase in motor activity (an index of antipsychotic efficacy). Locomotor activity (number of photobeam breaks) was measured in 5-min blocks throughout the entire 90-min testing session.
Experiment 2: effects of different numbers of drug exposure in the motor activity test apparatus on the inhibitory effect of an antipsychotic drug on phencyclidine-induced hyperlocomotion Experiment 1 did not control total drug exposure between each pair of drug groups. Therefore, the differential drug effects could be attributed either to this factor or to different drug-environment (home cage) pairings. In experiment 2, we controlled the total number of drug exposures between the groups. In addition, we directly manipulated the number of drug-environment pairings. Ninety-six rats (run in two cohorts of 48) were first randomly assigned to four groups (n = 24/group) that were subjected to sterile water, haloperidol, clozapine, or olanzapine treatment. Each treatment group was further divided randomly into three subgroups (n = 8/group) that differed in the number of drug exposures (i.e. 0, 2, and 4) in the motor activity test apparatus before the three PCPinduced hyperlocomotion probe tests.
For the 0-exposure subgroups (VEH-0, HAL-0, CLZ-0, OLZ-0), rats were injected with water, haloperidol (0.03 mg/kg, sc), clozapine (5.0 mg/kg, sc), or olanzapine (1.0 mg/kg, sc), followed by PCP (1.6 mg/kg, sc) 30 min later in their home cages for 4 consecutive days. The antipsychotic drugs and PCP were tested at a lower dose to explore the impact of drug dosage on the environmental modulation of antipsychotic efficacy in comparison with the results from experiment 1. In addition, a lower dose would better allow detection of any contextual control of a drug effect. One day after the last drug injection in the home cages, rats were tested in the three probe tests in the motor activity test apparatus. In each test, rats were injected with water, haloperidol (0.03 mg/kg, sc), clozapine (5.0 mg/kg, sc), or olanzapine (1.0 mg/kg, sc), followed by PCP (1.6 mg/kg, sc) 30 min later in the test apparatus. Their motor activities were recorded for the entire 90 min (30 min before and 60 min after the PCP injection), as in our previous work (Zhang and Li, 2012) . These subgroups had 0-day experience with the test apparatus before the probe tests.
For the 2-exposure subgroups (VEH-2, HAL-2, CLZ-2, OLZ-2), rats were injected with water, haloperidol (0.03 mg/kg, sc), clozapine (5.0 mg/kg, sc), or olanzapine (1.0 mg/kg, sc) and PCP (1.6 mg/kg, sc) at a 30-min interval in the home cages for the first 2 days and then in the test apparatus for the last 2 days; thus, they had a 2-day experience of the test apparatus before the three probe tests.
For the 4-exposure subgroups (VEH-4, HAL-4, CLZ-4, OLZ-4), rats received all of their 4-day drug treatments in the test apparatus before the three probe tests. As is apparent, the three subgroups in each treatment condition (e.g. HAL-0, HAL-2, and HAL-4) had an identical drug treatment history and only differed in the number of exposures to the test environment before the probe tests. Thus, any possible differences in locomotion during the probe tests among the three treatment subgroups would reflect the impact of previous drug exposure in the test environment on the efficacy of a drug in the inhibition of spontaneous motor activity (i.e. 30 min before PCP injection) and PCP-induced hyperlocomotion (i.e. 60 min after PCP injection).
Drugs
The injection solution of haloperidol (5 mg/ml ampoules, 5 mg/ml ampoules; Sabex Inc., Boucherville, Quebec, Canada) was obtained by mixing drugs with sterile water. The injection solution of phencyclidine hydrochloride (gift from National Institute on Drug Abuse Chemical Synthesis and Drug Supply Program) was obtained by mixing drugs with 0.9% saline. Clozapine (gift from the NIMH drug supply program) and olanzapine (Toronto Research Chemical Inc., Ontario, Canada) were dissolved in 1.5% glacial acetic acid distilled water. The doses of haloperidol (0.03 or 0.05 mg/kg), olanzapine (1.0 or 2.0 mg/kg), clozapine (5 and 10 mg/kg), and PCP (1.60 or 3.20 mg/kg) were chosen on the basis of our previous work (Sun et al., 2009 (Sun et al., , 2010 Zhang and Li, 2012; Feng et al., 2013) . All drugs were administered at 1.0 ml/kg, sc.
Statistical analysis
All data were expressed as mean + SEM. Data from the drug test sessions were analyzed using a mixed analysis of variance (ANOVA) with the between-subject factors of drug group and/or drug exposures (e.g. 0, 2, or 4) and the within-subject factor of test days, followed by post-hoc Fisher's least significant difference (LSD) tests. Differences between groups on the specific drug test days were analyzed using one-way ANOVAs, followed by post-hoc LSD tests. For all analyses, a P value of less than 0.05 was considered statistically significant and all data were analyzed using SPSS version 21 (IBM Inc., Armonk, New York, USA). Because Fisher's LSD test does not correct for multiple comparisons, a few instances when the P value was close to 0.05 should be treated with caution.
Results
Experiment 1: effects of previous antipsychotic treatment in the home cages on the inhibitory effect of an antipsychotic drug on phencyclidine-induced hyperlocomotion Previous drug exposure in the home-cage environment potentiated the acute inhibitory effect of haloperidol and olanzapine on spontaneous motor activity and phencyclidine-induced hyperlocomotion, but not that of clozapine Figure 1 shows the mean motor activity of the seven groups of rats during the 30 min before PCP injection and 60 min after PCP injection on the first drug test day. Acute haloperidol, olanzapine, or clozapine treatment inhibited spontaneous motor activity (Fig. 1a) and PCPinduced hyperlocomotion (Fig. 1b) . One-way ANOVA showed a significant main effect of group in the first 30 min before PCP injection [F(6, 41) = 27.20, P < 0.001] and the 60 min after PCP injection [F(6, 41) = 13.44, P < 0.001]. Post-hoc Fisher's LSD tests showed that all the antipsychotic-treated groups had significantly lower motor activity than the vehicle group (VEH + VEH) in the first 30 min (P < 0.003) and all except the VEH + HAL group also had significantly lower motor activity in the second 60 min (P < 0.002). The VEH + HAL had lower motor activity than the VEH + VEH group, but the difference was not significant.
Previous haloperidol or olanzapine, but not clozapine, treatment in the home cages also enhanced their inhibitory effect on spontaneous motor activity and PCPinduced hyperlocomotion on day 1. Post-hoc Fisher's LSD tests on each pair of haloperidol, olanzapine, and clozapine groups showed that the HAL + HAL group had significantly lower motor activity than the VEH + HAL in the 30 min before PCP (P < 0.02), and in the 60 min after PCP injection (P < 0.05). Similarly, the OLZ + OLZ Effect of home-cage antipsychotic treatment on the acute inhibitory effect of antipsychotic drugs on phencyclidine (PCP)-induced hyperlocomotion tested in a new motor activity apparatus. Locomotor activity was measured for 30 min after sterile water (VEH), haloperidol (HAL; 0.05 mg/kg), clozapine (CLZ; 10.0 mg/kg), or olanzapine (OLZ; 2.0 mg/kg) injection (a) and 60 min after PCP (3.2 mg/kg) injection (b) and expressed as mean + SEM for each group. *P < 0.05 relative to the VEH + VEH group; # P < 0.05 relative to the corresponding control groups that were treated with vehicle in the home cages (i.e. VEH + HAL or VEH + OLZ).
group also had significantly lower motor activity than the VEH + OLZ group in the first 30 min (P < 0.02) and in the 60 min after PCP injection (P < 0.005). In contrast, the two clozapine groups did not differ from each other during both periods. These findings suggest that previous haloperidol and olanzapine treatment, even in a different environment, still enhanced their acute inhibition of spontaneous motor activity and PCP-induced hyperlocomotion. The influence of previous clozapine treatment did not manifest an acute behavioral effect. These findings also indicate that the expression of haloperidol and olanzapine sensitization induced in the home-cage environment, manifested as an enhanced inhibition of spontaneous motor activity and PCPinduced hyperlocomotion, was less dependent on the context in which the previous drug exposure occurred.
Previous clozapine treatment in the home cages enhanced the development of clozapine tolerance Figure 2a shows the mean motor activity of the seven groups of rats during the 30-min test period before PCP injection throughout the 5 days of drug testing. A mixed ANOVA showed significant main effects of group [F(6, 41) = 12.60, P < 0.001] and test day [F(4, 164) = 89.04, P < 0.001], and a significant group × day interaction [F(24, 164) = 8.25, P < 0.001]. One-way ANOVAs on each test day indicated that on day 1, all antipsychotic-treated groups had significantly lower motor activity than the vehicle group (all P < 0.005), confirming their acute motor-suppressive effect. However, on day 5, only the two olanzapine groups had significantly lower motor activity than the vehicle group (P < 0.005), whereas the CLZ + CLZ group had a significantly higher motor activity (P < 0.001), indicating that there was a gradual development of clozapine tolerance in the home-cage clozapine treatment group. This observation was also supported by the finding that the CLZ + CLZ had significantly higher motor activity than the VEH + CLZ group on days 4 and 5 (P < 0.01). Figure 2b shows the mean motor activity during the 60-min test period after PCP injection. Once again, a mixed ANOVA showed significant main effects of group [F(6, 41) = 27.08, P < 0.001] and test day [F(4, 164) = 10.58, Effect of home-cage antipsychotic treatment on the inhibitory effect of antipsychotic drugs on phencyclidine (PCP)-induced hyperlocomotion throughout the 5 days of drug testing. (a) Locomotor activity was measured for 30 min after sterile water (VEH), haloperidol (HAL; 0.05 mg/kg), clozapine (CLZ; 10.0 mg/kg), or olanzapine (OLZ; 2.0 mg/kg) injection and expressed as mean + SEM for each group. (b) Locomotor activity was measured for 60 min after PCP injection and expressed as mean + SEM. *P < 0.05 relative to the VEH + VEH group; # P < 0.05 relative to the corresponding control groups that were treated with vehicle in the home cages (i.e. VEH + HAL or VEH + OLZ). P < 0.001], and a significant group × day interaction [F(24, 164) = 4.359, P < 0.001]. One-way ANOVAs and post-hoc tests on each test day indicated that all antipsychotic-treated groups (except the VEH + HAL group on day 1) showed significantly lower motor activity than the vehicle group throughout the drug test period (all P < 0.002) confirming their motor-suppressive effect on PCP-induced hyperlocomotion. Except on day 1, each pair of haloperidol and olanzapine groups did not differ from each other throughout the rest of the test days. The CLZ + CLZ group had marginally higher motor activity than the VEH + CLZ groups on day 5, but this difference failed to reach significance (P = 0.078).
To better differentiate the different impacts of homecage haloperidol and olanzapine exposure from that of clozapine exposure, we illustrated the time course of the motor activity in response to haloperidol, olanzapine, or clozapine treatment for each of the drug-pair groups (e.g. VEH + HAL and HAL + HAL) together with the vehicle group in 5-min blocks on day 1 and day 5 (Fig. 3) . The potentiated inhibition of previous haloperidol and olanzapine treatment on the first day was indexed by the finding that the HAL + HAL and OLZ + OLZ groups had consistently higher motor activity throughout the 90-min test period than the respective VEH + HAL and VEH + OLZ groups on day 1. Similarly, the reduced impact of previous clozapine on the last day was shown by the consistently reduced motor activity in the CLZ + CLZ group compared with the VEH + CLZ group on day 5. Experiment 2: effect of different numbers of drug exposure in the motor activity test apparatus on the inhibitory effect of an antipsychotic drug on phencyclidine-induced hyperlocomotion Previous haloperidol exposure in the test apparatus enhanced its efficacy in the inhibition of phencyclidineinduced hyperlocomotion, whereas previous clozapine and olanzapine did not Figure 4 shows the mean motor activity in the 30 min before and 60 min after PCP injection of the 12 subgroups on their three consecutive probe tests. All groups of rats had identical drug treatment history by this time, but different numbers of exposures to the test environment. For example, the 4-exposure subgroups had 4 days of antipsychotic (sterile water) + PCP treatment in the test apparatus (pairing) before the probes; the 2-exposure subgroups had 2 days of pairing and the 0-exposure subgroups had not been exposed to the test apparatus. To examine how different numbers of antipsychotic and test environment pairings (e.g. 4, 2, or 0) affected a drug's ability to suppress spontaneous motor activity and PCPinduced hyperlocomotion, we first carried out a mixed ANOVA (4 drug conditions × 3 exposure conditions × 3 test days). In the first 30 min of motor activity testing, there were significant main effects of treatment [F(3, 84 Because of the significant treatment × exposure interaction and test × exposure interaction, to specify how different numbers of test environment exposures affected each antipsychotic drug efficacy differently, we carried out mixed ANOVAs comparing the three subgroups within each treatment condition over the 3 probe test days (e.g. HAL-0, HAL-2, and HAL-4). For the three vehicle subgroups, a mixed ANOVA showed significant main effects of group [F(2, 21) = 18.86, P < 0.001] and test [F(2, 42) = 9.15, P < 0.001], and a significant group × test interaction [F(4, 42) = 8.11, P < 0.001] in the first 30 min. One-way ANOVAs, followed by post-hoc tests showed that the VEH-0 subgroup had significantly higher motor activity than the VEH-2 and VEH-4 subgroups on the first 2 days of testing (P < 0.01). Because the VEH-0 group had no previous experience of the test apparatus before the probe tests, the higher motor activity in this subgroup relative to the other two vehicle subgroups could be attributed to the novelty-induced increase in motor activity. In the second 60 min, neither the group effect [F(2, 21) = 0.59, NS] nor the group × test interaction [F(4, 42) = 2.176, P = 0.088] was significant. For the three haloperidol subgroups, a mixed ANOVA showed significant main effects of group [F(2, 21) = 8.99, P < 0.002] and test [F(2, 42) = 13.08, P < 0.001], and a significant group × test interaction [F(4, 42) = 7.73, P < 0.001] in the first 30 min. The HAL-4 subgroup had significantly lower motor activity than the HAL-0 group on the first day (P < 0.005), and lower motor activity than the HAL-0 group on the second day (P < 0.01). In the second 60 min, the group effect was significant [F(2, 21) = 6.44, P < 0.01], the test effect was significant [F(2, 42) = 11.63, P < 0.001] and the group × test interaction was also significant [F(4, 42) = 4.18, P < 0.01]. The HAL-4 subgroup had significantly lower motor activity than the HAL-0 group on the first day (P < 0.005), and the last day (P < 0.05). These results suggest that repeated haloperidol exposure in the test apparatus enhanced the efficacy of HAL in the inhibition of spontaneous motor activity and PCP-induced hyperlocomotion in the same environment.
For the three clozapine subgroups, a mixed ANOVA showed no significant main effect of group [F(2, 21) = 0.86, NS] but a significant group × test interaction [F(4, 42) = 3.44, P < 0.02] in the first 30 min. Oneway ANOVAs on each test day did not find a significant group effect (all P > 0.06). In the following 60 min, the group effect, the test effect, and their interaction were all nonsignificant (P > 0.075). These results indicate that repeated clozapine exposure in the test apparatus did not alter its efficacy in the inhibition of spontaneous motor activity and PCP-induced hyperlocomotion in the same test environment. 
Effect of home-cage antipsychotic treatment on the inhibitory effect of antipsychotic drugs on phencyclidine (PCP)-induced hyperlocomotion on day 1 and day 5 of drug testing. Locomotor activity was measured in eighteen 5-min blocks for the two haloperidol groups (VEH + HAL and HAL + HAL) (a), two olanzapine groups (VEH + OLZ and OLZ + OLZ) (b), and two clozapine groups (VEH + CLZ and CLZ + CLZ) (c), together with the vehicle groups. CLZ, clozapine; HAL, haloperidol; OLZ, olanzapine; VEH, vehicle.
Contextual impact of antipsychotic-like effect Sun et al. 283 For the three olanzapine subgroups, in the first 30 min, a mixed ANOVA showed significant main effects of group [F(2, 21) = 8.86, P < 0.002] and test [F(2, 42) = 14.51, P < 0.001], and a significant group × test interaction [F(4, 42) = 6.65, P < 0.001]. The OLZ-0 subgroup had significantly higher motor activity than the other two OLZ subgroups on the first day (P < 0.001), and higher motor activity than the OLZ-2 subgroup on the third day (P < 0.05). In the following 60 min, the group effect, the test effect, and their interaction were all nonsignificant (P > 0.24). These results suggest that repeated olanzapine exposure in the test apparatus primarily enhanced its efficacy in the inhibition of spontaneous motor activity.
Taken together, the results from this experiment suggest that repeated pairing of haloperidol and olanzapine treatment with the test environment enhanced their efficacy of inhibition of spontaneous motor activity. Repeated pairing of haloperidol treatment with the test environmental also enhanced its inhibition of PCPinduced hyperlocomotion, whereas repeated clozapine or olanzapine and environment pairing had little effect on this measure.
Discussion
The present study provides evidence that specific experimental parameters and drug treatments play a role in determining whether the contextual cues associated with antipsychotic drug administration exert control over the expression of antipsychotic efficacy. In experiment 1, we found that repeated administration of haloperidol (0.05 mg/kg, sc) and olanzapine (2.0 mg/kg, sc), even in the home cages, potentiated their inhibition of PCP (3.20 mg/kg, sc)-induced hyperlocomotion in the motor activity test boxes (a novel environment). Furthermore, relative to the VEH + CLZ group, pretreatment with clozapine in the home cage decreased its effectiveness on spontaneous activity over the 5-day test period in the motor test environment. These findings suggest that Activity count (mean
Previous haloperidol exposure in the test apparatus enhanced its efficacy of inhibition of phencyclidine (PCP)-induced hyperlocomotion, whereas previous clozapine and olanzapine did not. Locomotor activity in the 30 min before (a) and 60 min after PCP injection (b) of the 12 subgroups across the three days of PCP-induced hyperlocomotion testing are expressed as mean + SEM. under certain test conditions, antipsychotic sensitization or tolerance could be less impacted by environmental cues. This conclusion was consistent with our finding in experiment 2 that repeated administration of clozapine (5.0 mg/kg, sc) or olanzapine (1.0 mg/kg, sc) for 4 consecutive days, irrespective of where these treatments occurred (e.g. 2 days in the home cage and 2 days in the test apparatus or 4 days in the home cage and 0 day in the test apparatus), had a similar level of inhibition on PCP (1.6 mg/kg, sc)-induced hyperlocomotion over the 3-day probe test period. In contrast, the observation that rats that received 4-day haloperidol (0.03 mg/kg, sc) treatment in the test apparatus had significantly lower motor activity than those that received 0-day treatment, despite their identical drug treatment history, does support the conclusion that the environment associated with repeated drug administration can powerfully modulate the expression of antipsychotic efficacy.
The contextual control of the behavioral efficacy of an antipsychotic drug is a relatively less studied topic. Evidence supporting both context independence and context dependence has been reported in the literature. For example, Sanger (1985) reported that repeated haloperidol or clozapine treatment, whether inside the test environment or outside, has little impact on the development of haloperidol sensitization or clozapine tolerance in a conditioned avoidance response model. However, in a similar conditioned avoidance response test, we showed that home-cage haloperidol (0.05 mg/kg) and olanzapine (1.0 mg/kg) treatment did not increase their behavioral efficacy of inhibition of avoidance response, indicating a context-dependent feature Sparkman and Li, 2012) . Similarly, Schmidt's group also reported that intermittent haloperidol treatment and repeated catalepsy testing led to an intensification of catalepsy over time and that this increase was completely context specific as context changes abolished catalepsy sensitization (Amtage and Schmidt, 2003; Klein and Schmidt, 2003) . Therefore, the environmental impact of a drug effect is dependent on the specific test conditions, including the selected behavioral responses, drug types, drug doses, number of drug treatments, etc. It is not a question of whether environmental cues play a role in the regulation of a drug effect, but under what exact conditions. This point was also supported in our recent study of the environmental and behavioral controls of the expression of clozapine tolerance (Feng et al., 2013) . Using an acrossmodel transfer paradigm, we first treated rats repeatedly with clozapine (2.5-10.0 mg/kg, sc) in either the conditioned avoidance response task or the PCP (1.6 mg/kg, sc)-induced hyperlocomotion test for 5 consecutive days. We then switched them to a different test and tested them under clozapine for another 5 days. When switching from the avoidance task to the PCP test, rats previously treated with clozapine in the avoidance task did not show an immediately weakened inhibition of PCP-induced hyperlocomotion compared with those treated with clozapine for the first time, but showed a significantly weaker inhibition over time. This finding matches perfectly with our finding from experiment 1, suggesting that change of environment only affects the acute effect of clozapine, but has no effect on its tolerance effect.
In our previous study (Sun et al., 2009) , we showed that repeated administration of clozapine at 10.0 mg/kg maintained its inhibition of spontaneous motor activity and PCP-induced hyperlocomotion over the 5 test days, a finding replicated in the present study (Fig. 2b) . Because the VEH + PCP group showed a progressive increase in motor activity over days, the persistent inhibition in the VEH + CLZ group indicates a sensitization-like effect, especially during the repeated drug test phase. This sensitization-like effect seems to be weaker in the CLZ + CLZ group relative to the VEH + CLZ group, as indicated by the significantly higher motor activity in the CLZ + CLZ group compared with the VEH + CLZ group in the first 30 min of testing on days 4 and 5, and marginally significant higher motor activity in the second 60 min of testing on day 5. Although we interpreted this finding as reflecting the home-cage clozapine-induced tolerance development, it could also be interpreted as the consequence of home-cage clozapine treatment that prevented the appearance of a sensitization-like effect. The exact nature of this previous clozapine effect needs to be further investigated.
Studies of the contextual control of drug effects typically compare a 'paired' group (a group that receives drug injections in the test environment) with an 'unpaired' group (a group that receives vehicle injections in the test environment and the drug in the home cage) (Poulos and Hinson, 1982; Amtage and Schmidt, 2003) . The influence of environment is assessed on a test day, when all animals receive a challenge injection of the drug in the test environment. If a stronger drug effect was detected in the 'paired' group, this would suggest that environmental stimuli have an influence on the drug effect (Robinson et al., 1998) . Experiment 2 used this approach and found that only repeated pairings of haloperidol treatment in the test apparatus enhanced the efficacy of haloperidol in the inhibition of spontaneous motor activity and PCP-induced hyperlocomotion as the HAL-4 subgroup had significantly lower motor activity than the HAL-0 group in the 30-min and second 60-min test periods. This enhanced HAL effect occurred because HAL, administered at this low dose (0.03 mg/kg) in the test environment for the first time, could not inhibit a novelty-induced increase in motor activity as shown in the HAL-0 group. In contrast, repeated clozapine/olanzapine pairings in the test environment produced little alteration of their effects. These results further suggest that the specific conditions govern the impact of environmental cues on a drug effect. Under the current conditions, the circumstances surrounding drug administration had a large impact on the behavioral efficacy of haloperidol, but not on that of clozapine and olanzapine. The reason for this differential impact on different antipsychotic drugs is not entirely clear. One possibility is that haloperidol has a stronger antagonist action on the D 2 receptor and tighter D 2 receptor binding than olanzapine and clozapine (Kapur and Seeman, 2000) , and multiple behavioral effects mediated by dopamine systems are typically modulated by environmental cues (Anagnostaras and Robinson, 1996; Robinson et al., 1998; Anagnostaras et al., 2002) .
One limitation of the present study is that only one dose of each antipsychotic drug was tested in each experiment. Therefore, the results from this study should be considered together with, and also in the context of, evidence from our previous studies Sparkman and Li, 2012; Zhang and Li, 2012; Feng et al., 2013) . Overall, the evidence seems to support the conclusion that environmental cues and behavioral responses can have a powerful impact on the inhibitory effect of an antipsychotic drug on PCP-induced hyperlocomotion and on conditioned avoidance responding (two well-validated behavioral measures of antipsychotic-like activity). However, such an impact could be limited by certain test conditions, such as the degree of similarity between different test environments, drug doses, and number of drug treatments.
